Annual Cash & Cash Equivalents
$15.65 M
-$11.57 M-42.51%
December 31, 2023
Summary
- As of February 8, 2025, ANTX annual cash & cash equivalents is $15.65 million, with the most recent change of -$11.57 million (-42.51%) on December 31, 2023.
- During the last 3 years, ANTX annual cash & cash equivalents has risen by +$11.58 million (+284.45%).
- ANTX annual cash & cash equivalents is now -42.51% below its all-time high of $27.22 million, reached on December 31, 2022.
Performance
ANTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$33.50 M
+$6.74 M+25.16%
September 30, 2024
Summary
- As of February 8, 2025, ANTX quarterly cash and cash equivalents is $33.50 million, with the most recent change of +$6.74 million (+25.16%) on September 30, 2024.
- Over the past year, ANTX quarterly cash and cash equivalents has increased by +$8.81 million (+35.68%).
- ANTX quarterly cash and cash equivalents is now -59.40% below its all-time high of $82.52 million, reached on March 31, 2022.
Performance
ANTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ANTX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -42.5% | +35.7% |
| 3 y3 years | +284.4% | +35.7% |
| 5 y5 years | +284.4% | +35.7% |
ANTX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.5% | +29.4% | -59.4% | +177.0% |
| 5 y | 5-year | -42.5% | +284.4% | -59.4% | +177.0% |
| alltime | all time | -42.5% | +284.4% | -59.4% | +177.0% |
AN2 Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $33.50 M(+25.2%) |
| Jun 2024 | - | $26.77 M(+8.4%) |
| Mar 2024 | - | $24.69 M(+57.8%) |
| Dec 2023 | $15.65 M(-42.5%) | $15.65 M(-52.0%) |
| Sep 2023 | - | $32.62 M(-20.1%) |
| Jun 2023 | - | $40.81 M(+52.8%) |
| Mar 2023 | - | $26.71 M(-1.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $27.22 M(+125.0%) | $27.22 M(-5.5%) |
| Sep 2022 | - | $28.80 M(-29.1%) |
| Jun 2022 | - | $40.62 M(-50.8%) |
| Mar 2022 | - | $82.52 M(+582.1%) |
| Dec 2021 | $12.10 M(+197.2%) | - |
| Dec 2021 | - | $12.10 M |
| Dec 2020 | $4.07 M | - |
FAQ
- What is AN2 Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for AN2 Therapeutics?
- What is AN2 Therapeutics annual cash & cash equivalents year-on-year change?
- What is AN2 Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for AN2 Therapeutics?
- What is AN2 Therapeutics quarterly cash and cash equivalents year-on-year change?
What is AN2 Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ANTX is $15.65 M
What is the all time high annual cash & cash equivalents for AN2 Therapeutics?
AN2 Therapeutics all-time high annual cash & cash equivalents is $27.22 M
What is AN2 Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ANTX annual cash & cash equivalents has changed by -$11.57 M (-42.51%)
What is AN2 Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ANTX is $33.50 M
What is the all time high quarterly cash and cash equivalents for AN2 Therapeutics?
AN2 Therapeutics all-time high quarterly cash and cash equivalents is $82.52 M
What is AN2 Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ANTX quarterly cash and cash equivalents has changed by +$8.81 M (+35.68%)